ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
발작성 야간혈색소뇨증(PNH) 치료 시장 규모는 2025년 54억 6,000만 달러에서 2026년부터 2034년까지 CAGR 11.77%로 성장하여 2034년에는 148억 6,000만 달러에 달할 것으로 예측됩니다.
발작성 야간혈색소뇨증(PNH) 치료 시장은 질환에 대한 이해의 심화 및 표적 치료제 개발을 배경으로 괄목할 만한 발전을 보이고 있습니다. 적혈구 파괴를 특징으로 하는 희귀하고 쇠약해지는 혈액질환인 PNH는 그 복잡한 특성으로 인해 기존에는 치료의 어려움을 겪어왔습니다. 그러나 최근 보체 억제제 등 단클론항체 치료의 획기적인 발전으로 인해 이 질환의 관리가 획기적으로 변화하고 있으며, 환자의 치료 성과와 삶의 질이 향상되고 있습니다.
PNH의 유병률 증가와 의료진의 인식 개선으로 효과적인 치료법에 대한 수요가 증가하고 있습니다. 진단 기술의 발전에 따라 더 많은 환자를 식별하고 치료할 수 있게 되어 시장 성장을 더욱 촉진하고 있습니다. 또한, 현재 진행 중인 임상시험 및 연구 프로젝트에서는 병용요법 및 새로운 치료법 개발에 초점을 맞추고 있어 PNH의 치료 옵션을 확대할 수 있을 것으로 기대됩니다. 기존 치료법으로 충분한 효과를 얻지 못하는 환자들의 미충족 수요를 충족시키기 위해 이러한 혁신 노력은 매우 중요합니다.
또한, 맞춤형 의료에 대한 관심이 높아지면서 PNH 치료 시장에도 영향을 미치고 있습니다. 환자 개개인의 프로파일과 유전자 마커를 기반으로 한 치료 계획을 수립하는 것이 점점 더 현실화되어 보다 효과적이고 표적화된 개입이 가능해졌습니다. 제약기업과 연구기관의 협력은 효능을 높이고 부작용을 최소화하는 차세대 치료제 개발을 촉진하고 있습니다. 결론적으로, PNH 치료 시장은 혁신성, 인지도 향상, 그리고 이 어려운 치료 영역에서 환자 결과 개선에 대한 노력으로 인해 견조한 성장이 예상됩니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 발작성 야간혈색소뇨증(PNH) 치료 시장 : 치료 유형별
제5장 세계의 발작성 야간혈색소뇨증(PNH) 치료 시장 : 투여 경로별
제6장 세계의 발작성 야간혈색소뇨증(PNH) 치료 시장 : 연령층별
제7장 세계의 발작성 야간혈색소뇨증(PNH) 치료 시장 : 최종사용별
제8장 세계의 발작성 야간혈색소뇨증(PNH) 치료 시장 : 지역별
제9장 경쟁 구도
제10장 기업 개요
KSM
영문 목차
영문목차
The Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market size is expected to reach USD 14.86 Billion in 2034 from USD 5.46 Billion (2025) growing at a CAGR of 11.77% during 2026-2034.
The paroxysmal nocturnal hemoglobinuria (PNH) treatment market is experiencing significant advancements, driven by a deeper understanding of the disease and the development of targeted therapies. PNH, a rare and debilitating blood disorder characterized by the destruction of red blood cells, has historically posed challenges in treatment due to its complex nature. However, recent breakthroughs in monoclonal antibody therapies, such as complement inhibitors, have revolutionized the management of this condition, offering patients improved outcomes and quality of life.
The increasing prevalence of PNH, coupled with heightened awareness among healthcare professionals, is propelling the demand for effective treatment options. As diagnostic techniques improve, more patients are being identified and treated, further driving market growth. Additionally, ongoing clinical trials and research initiatives are focused on exploring combination therapies and novel treatment modalities, which are expected to expand the therapeutic landscape for PNH. This focus on innovation is crucial, as it addresses the unmet needs of patients who may not respond adequately to existing therapies.
Furthermore, the growing emphasis on personalized medicine is influencing the PNH treatment market. Tailoring treatment plans based on individual patient profiles and genetic markers is becoming increasingly feasible, allowing for more effective and targeted interventions. The collaboration between pharmaceutical companies and research institutions is fostering the development of next-generation therapies that aim to enhance efficacy and minimize side effects. In conclusion, the PNH treatment market is set for robust growth, characterized by innovation, increased awareness, and a commitment to improving patient outcomes in this challenging therapeutic area.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Treatment Type
Complement Inhibitors
Iron Therapy
Immunosuppressant Drugs
Bone Marrow Transplantation
Others
By Route of Administration
Oral
Parenteral
By Age Group
Pediatric
Adult
By End-use
Hospitals
Specialty clinics
Homecare settings
Others
COMPANIES PROFILED
Amgen Inc, Apellis Pharmaceuticals, Inc, AstraZeneca Plc, Childrens National Hospital, F HoffmannLa Roche Ltd, Memorial Sloan Kettering Cancer Center, Novartis AG, Pfizer, Inc, Regeneron Pharmaceuticals Inc, Teva Pharmaceuticals Industries Ltd, UCLA Health, University of Rochester Medical Center
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1 Information Analysis
1.3.2 Market Formulation & Data Visualization
1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
3.4.1 Standards & Compliance
3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
3.5.1 Market Drivers
3.5.2 Market Restraints
3.5.3 Market Opportunities
3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
Chapter 4. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)
4.1. Market Analysis, Insights and Forecast Treatment Type
4.2. Complement Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Iron Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Immunosuppressant Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Bone Marrow Transplantation Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)
5.1. Market Analysis, Insights and Forecast Route Of Administration
5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY AGE GROUP 2022-2034 (USD MN)
6.1. Market Analysis, Insights and Forecast Age Group
6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY END-USE 2022-2034 (USD MN)
7.1. Market Analysis, Insights and Forecast End-use
7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.3. Specialty clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.4. Homecare settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 8. GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET: BY REGION 2022-2034(USD MN)
8.1. Regional Outlook
8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.2.1 By Treatment Type
8.2.2 By Route Of Administration
8.2.3 By Age Group
8.2.4 By End-use
8.2.5 United States
8.2.6 Canada
8.2.7 Mexico
8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.3.1 By Treatment Type
8.3.2 By Route Of Administration
8.3.3 By Age Group
8.3.4 By End-use
8.3.5 United Kingdom
8.3.6 France
8.3.7 Germany
8.3.8 Italy
8.3.9 Russia
8.3.10 Rest Of Europe
8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.4.1 By Treatment Type
8.4.2 By Route Of Administration
8.4.3 By Age Group
8.4.4 By End-use
8.4.5 India
8.4.6 Japan
8.4.7 South Korea
8.4.8 Australia
8.4.9 South East Asia
8.4.10 Rest Of Asia Pacific
8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.5.1 By Treatment Type
8.5.2 By Route Of Administration
8.5.3 By Age Group
8.5.4 By End-use
8.5.5 Brazil
8.5.6 Argentina
8.5.7 Peru
8.5.8 Chile
8.5.9 South East Asia
8.5.10 Rest of Latin America
8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
8.6.1 By Treatment Type
8.6.2 By Route Of Administration
8.6.3 By Age Group
8.6.4 By End-use
8.6.5 Saudi Arabia
8.6.6 UAE
8.6.7 Israel
8.6.8 South Africa
8.6.9 Rest of the Middle East And Africa
Chapter 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments
9.2. Company Categorization
9.3. Supply Chain & Channel Partners (based on availability)
9.4. Market Share & Positioning Analysis (based on availability)
9.5. Vendor Landscape (based on availability)
9.6. Strategy Mapping
Chapter 10. COMPANY PROFILES OF GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY
